Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
Clinical trial NCT03153202 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03153202
- Sponsor
- Joshua Brody
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-07-14
- Primary completion
- 2025-11-01
- Enrollment
- 23
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.